An Open-Label, Multi-Center Phase I/II Dose Escalation Study to Investigate the Safety and Tolerability of Multiple Doses of Oral Tasidotin HCL in Patients with Advanced Solid Tumors (part A), and combination of Oral Tasidotin HCl with Intravenous DTIC in Chemotherapy Naive Patients with Malignant Melanoma (part B).
Phase of Trial: Phase I/II
Latest Information Update: 28 Jan 2014
At a glance
- Drugs Tasidotin (Primary) ; Dacarbazine
- Indications Malignant melanoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 21 Jul 2011 New trial record